Thursday, May 23, 2013

• Elan Announces Pricing of US$850 Million in Aggregate Principal Amount of Senior Notes Due 2021Business Wire( (Thu, May 23)
• Elan Corporation, plc’s Board of Directors Unanimously Reject Royalty Pharma’s Revised Tender OfferBusiness Wire( (Thu, May 23)
• Royalty Pharma Reduces Acceptance Condition to 50% Plus One SharePR Newswire( (Thu, May 23)

Monday, May 20, 2013

• Elan’s Response to Royalty Pharma AnnouncementBusiness Wire( (Mon, May 20)
• Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All CashPR Newswire( (Mon, May 20)
• Elan Announces Transactions: Decisively Transforming the CompanyBusiness Wire( (Mon, May 20)
• Elan Announces Proposed Offering of US$800.0 Million in Aggregate Principal Amount of Senior Notes Due 2021Business Wire( (Mon, May 20)

Wednesday, May 15, 2013

• Elan Announces Publication of Response DocumentBusiness Wire( (Wed, May 15)

Monday, May 13, 2013

• Elan Provides Additional Commentary on Elan/Theravance Royalty Participation AgreementBusiness Wire( (Mon, May 13)
• Theravance and Elan Enter Into a $1.0 Billion Royalty Participation AgreementBusiness Wire( (Mon, May 13)
• Theravance and Elan Enter Into a $1.0 Billion Royalty Participation AgreementMarketwired( (Mon, May 13)

Thursday, May 2, 2013

• Royalty Pharma Submits Formal Cash Offer For Elan Corporation, plc ("Elan")PR Newswire( (Thu, May 2)

Thursday, April 25, 2013

• Elan Announces Publication of Notice of 2013 Annual General Meeting & Directors’ RetirementBusiness Wire( (Thu, Apr 25)